COMPARATIVE EFFECTIVENESS AND ECONOMIC EVALUATION OF THERAPIES IN ADVANCED NON-SMALL-CELL LUNG CANCER: A PRECISION MEDICINE PERSPECTIVE

Abstract

THIS THESIS ADDRESSED FOUR KEY KNOWLEDGE GAPS ON THE EFFICACY AND COST-EFFECTIVENESS OF TREATMENTS IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) [1,2]. SYSTEMATIC SYNTHESIS OF CURRENT EVIDENCE FOR OPTIMAL TREATMENT STRATEGIES IN THE FIRST-LINE AND MAINTENANCE SETTING FOR ADVANCED NSCLC WAS PERFORMED [1,2]. FURTHER, IT ELUCIDATED PRECISION MEDICINE STRATEGIES TO OPTIMIZE TREATMENT BENEFITS [1,2]. FINALLY, IT EVALUATED THE COST-EFFECTIVENESS OF MAINTENANCE REGIMENS FOR ADVANCED NSCLC. THIS THESIS DEMONSTRATED CLINICAL BENEFITS OF PARTICULAR FIRST-LINE WITH MAINTENANCE TREATMENTS AND COST-EFFECTIVENESS OF MAINTENANCE TREATMENTS FOR PATIENTS WITH ADVANCED NSCLC AND HIGHLIGHTED THE IMPORTANCE OF SELECTING PATIENTS BY CLINICAL AND/OR MOLECULAR BIOMARKERS FOR MAXIMUM CLINICAL AND COST-EFFECTIVENESS BENEFITS [1,2].